STK3/STK4 Antibody

Fundamental Characteristics of STK3/STK4 Antibody

STK3/STK4 antibodies are immunological reagents designed to detect and quantify STK3 (also known as MST2) and STK4 (also known as MST1) proteins. These proteins are mammalian homologs of the Sterile-20 (Ste20) kinase found in Saccharomyces cerevisiae and function as stress-activated, pro-apoptotic kinases . Following caspase-cleavage, these kinases translocate to the nucleus where they induce chromatin condensation and DNA fragmentation, critical steps in programmed cell death .

The commercially available antibodies recognize various epitopes of STK3/STK4 proteins, with some specifically targeting phosphorylated forms such as the pThr183 residue . These antibodies are primarily generated in rabbits as polyclonal antibodies, though monoclonal varieties also exist. The immunogens typically consist of synthetic peptides corresponding to specific regions of human STK3 or STK4 proteins, often conjugated to carrier proteins like KLH (Keyhole Limpet Hemocyanin) .

Applications in Research Settings

STK3/STK4 antibodies serve critical functions across multiple molecular and cellular techniques, enabling detailed investigations of these kinases in various biological contexts.

Western Blotting

Western blotting remains the primary application for STK3/STK4 antibodies, with recommended dilutions typically ranging from 1:300 to 1:5000 . This technique allows researchers to determine protein expression levels and phosphorylation states in various cell types and tissues. Western blot analysis has revealed inverse relationships between STK3 and STK4 protein expression across prostate cancer cell lines, suggesting potential compensatory mechanisms .

Immunohistochemistry

In immunohistochemical applications, STK3/STK4 antibodies can detect protein expression in both frozen and paraffin-embedded tissues. Recommended dilutions range from 1:50 to 1:500, depending on the specific antibody and application . This technique has been instrumental in analyzing STK4 expression patterns in endometrial cancer tissues, where it has shown potential as a prognostic marker .

Immunofluorescence

Immunofluorescence with STK3/STK4 antibodies enables visualization of protein localization within cellular compartments. This application has been crucial in demonstrating the nuclear translocation of STK4 following T cell receptor (TCR) stimulation in regulatory T cells, where it forms a complex with Foxp3 and NF-κB p65 .

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA applications with STK3/STK4 antibodies provide quantitative measurements of protein levels. Recommended dilutions typically range from 1:500 to 1:40000, depending on the specific antibody and assay conditions .

Biological Functions of STK3/STK4 Proteins

Understanding the biological roles of STK3/STK4 provides context for the significance of antibodies targeting these proteins in research applications.

Hippo Signaling Pathway

STK3 and STK4 serve as key components of the Hippo signaling pathway, which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis . In this pathway, STK3/STK4, in complex with their regulatory protein SAV1, phosphorylate and activate LATS1/2 kinases, which in turn phosphorylate and inactivate YAP1 oncoprotein and WWTR1/TAZ . Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus, thereby regulating cellular genes important for cell proliferation, cell death, and cell migration .

Autophagy Regulation

Research utilizing STK3/STK4 antibodies has revealed their unexpected role in autophagy regulation. STK3 and STK4 phosphorylate LC3 (microtubule-associated protein 1 light chain 3) at threonine 50, a critical step for autophagosome-lysosome fusion . Loss of this phosphorylation blocks autophagy and compromises cellular capacity to clear intracellular bacteria, highlighting the importance of STK3/STK4 in immune defense mechanisms .

Immune Regulation

STK4 plays a critical role in immune regulation, particularly in regulatory T (Treg) cells. TCR signaling in Treg cells induces the nuclear translocation of STK4, leading to the formation of a Stk4/NF-κB p65/Foxp3 complex that regulates Foxp3 and p65-dependent transcriptional programs . This complex is stabilized by STK4-dependent phosphorylation of Foxp3 serine 418, and STK4 deficiency in Treg cells precipitates fatal autoimmune lymphoproliferative disease in mice .

Research Findings Utilizing STK3/STK4 Antibodies

STK3/STK4 antibodies have facilitated numerous significant discoveries regarding these kinases' functions and implications in disease states.

Autophagy Mechanisms

Research employing STK3/STK4 antibodies has demonstrated that these kinases phosphorylate LC3 on threonine 50, a critical step for fusion between autophagosomes and lysosomes . In STK3/STK4-deficient mouse embryonic fibroblasts, researchers observed:

1. Increased abundance of autophagic structures

2. Elevated total levels of endogenous LC3-II

3. Dramatically higher numbers of endogenous LC3 puncta, even under fully-fed conditions

4. Impaired ability to clear intracellular bacteria

Importantly, reintroduction of active STK4, but not kinase-dead STK4, restored normal autophagy function, confirming the kinase activity dependence of this process .

Regulatory T Cell Function

Antibody-based studies have revealed an essential role for STK4 in regulatory T cell activation and immune tolerance. Following TCR stimulation, STK4 translocates to the nucleus where it:

1. Forms a trimolecular complex with Foxp3 and NF-κB p65

2. Phosphorylates Foxp3 at serine 418, stabilizing the complex

3. Regulates Foxp3 and p65-dependent transcriptional programs

The complex formation was directly demonstrated through co-immunoprecipitation studies with STK3/STK4 antibodies, and the translocation was inhibited by treatment with XMU-MP-1, a specific STK4 kinase inhibitor .

Cancer Progression and Prognosis

STK3/STK4 antibodies have contributed to understanding these kinases' roles in cancer. In prostate cancer, western blot analysis revealed an inverse relationship between STK3 and STK4 protein expression across cell lines . Progression-free survival analysis of patients from the TCGA prostate adenocarcinoma cohort showed significantly decreased time to progression in STK3-amplified patients compared to STK3-diploid patients (Hazard Ratio = 1.94, p=0.024) .

Similarly, in endometrial cancer, immunohistochemistry with STK4 antibodies demonstrated that STK4 protein expression follows different trends in endometrioid versus serous subtypes . Higher expression was associated with worse prognosis in serous endometrial cancer, suggesting potential utility as a prognostic marker .

Therapeutic Implications and Targeting STK3/STK4

Research using STK3/STK4 antibodies has identified these kinases as potential therapeutic targets across multiple diseases.

Cancer Therapeutics

STK3/STK4 inhibitors, such as XMU-MP-1, have demonstrated anti-proliferative effects in various cancer models:

1. Dose-dependent decreases in proliferation rates of LNCaP, 22RV1, and PC-3 prostate cancer cells

2. Significant reduction in growth of LAPC-4 3D spheroids

3. Decreased levels of cell cycle progression marker cyclin D1 after 18 hours of treatment

4. Similar growth inhibition in MDA-MB-231 and SUM-149 breast cancer cells

Notably, STK3 depletion promotes apoptotic cell death in some human acute myeloid leukemia cell lines and primary cells, and genetic inactivation of STK4 in multiple myeloma cells decreases their proliferation and induces a robust apoptotic response .

Immune-Related Disorders

STK4 deficiency in humans is associated with recurrent infections, likely due to neutropenia and lymphopenia, highlighting the importance of these kinases in immune function . The finding that STK4 forms a complex with Foxp3 and NF-κB p65 in regulatory T cells suggests potential therapeutic applications in autoimmune diseases where Treg cell function is dysregulated .

Future Research Directions

The continued development and application of STK3/STK4 antibodies will enable several promising research directions:

Development of Phospho-Specific Antibodies

The availability of antibodies specifically recognizing phosphorylated forms of STK3/STK4, such as those targeting pThr183, allows for more detailed investigation of activation states in various physiological and pathological contexts . Future development of antibodies targeting additional phosphorylation sites could provide further insights into the regulation of these kinases.

Biomarker Development

The finding that STK4 expression pattern could serve as a prognostic marker for serous endometrial cancer suggests potential clinical applications . Further research with STK3/STK4 antibodies could validate these findings and extend them to additional cancer types, potentially leading to the development of diagnostic or prognostic tests.

Therapeutic Target Validation

The identification of STK3/STK4 as potential therapeutic targets in prostate cancer, breast cancer, and hematological malignancies warrants further investigation . Antibodies against these kinases will be essential tools in validating these targets and developing effective therapeutic strategies.